<!DOCTYPE html>
<html lang="zh">
<head>
  <meta charset="UTF-8">
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <title>Application of Immune Checkpoint Inhibitors in Cancer - PMC</title>
  <style>
    body {
      font-family: "Helvetica Neue", "Noto Sans TC", sans-serif;
      max-width: 720px;
      margin: 2em auto;
      padding: 0 1em;
      color: #333;
      line-height: 1.8;
      background: #fff;
    }
    h1, h2, h3 {
      text-align: center;
      color: #222;
    }
    .lang-switcher {
      text-align: center;
      margin-bottom: 2em;
    }
    .lang-btn {
      margin: 0 0.5em;
      padding: 0.4em 1em;
      border: none;
      background-color: #eee;
      border-radius: 4px;
      cursor: pointer;
      font-weight: bold;
    }
    .lang-btn.active {
      background-color: #007acc;
      color: white;
    }
    ul {
      padding-left: 1.2em;
    }
    a {
      color: #007acc;
      text-decoration: none;
    }
    a:hover {
      text-decoration: underline;
    }
    img {
      max-width: 100%;
      height: auto;
    }
    .share-block {
      text-align: center;
      margin: 1em 0 2em;
      font-size: 0.95em;
    }
    .share-block a svg {
      width: 24px;
      height: 24px;
      display: inline-block;
      vertical-align: middle;
      margin: 0 0.4em;
      transition: transform 0.2s ease;
      cursor: pointer;
    }
    .share-block a svg:hover {
      transform: scale(1.2);
    }
  </style>
</head>
<body>
  <h1>Application of Immune Checkpoint Inhibitors in Cancer - PMC</h1>
  
  <div class="share-block">
    <span>ğŸ”— åˆ†äº«é€™ç¯‡SEOï¼š</span>
    <a href="https://www.facebook.com/sharer/sharer.php?u=https%3A%2F%2Fbreastcancer-tech.github.io%2Fbreast-cancer%2Fapplication-of-immune-checkpoint-inhibitors-in-cancer-pmc-seo.html" target="_blank" title="Facebook">
      <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 512 512"><!--!Font Awesome Free 6.7.2 by @fontawesome - https://fontawesome.com License - https://fontawesome.com/license/free Copyright 2025 Fonticons, Inc.--><path d="M512 256C512 114.6 397.4 0 256 0S0 114.6 0 256C0 376 82.7 476.8 194.2 504.5V334.2H141.4V256h52.8V222.3c0-87.1 39.4-127.5 125-127.5c16.2 0 44.2 3.2 55.7 6.4V172c-6-.6-16.5-1-29.6-1c-42 0-58.2 15.9-58.2 57.2V256h83.6l-14.4 78.2H287V510.1C413.8 494.8 512 386.9 512 256h0z"/></svg>
    </a>
    <a href="https://x.com/intent/tweet?url=https%3A%2F%2Fbreastcancer-tech.github.io%2Fbreast-cancer%2Fapplication-of-immune-checkpoint-inhibitors-in-cancer-pmc-seo.html&text=Application%20of%20Immune%20Checkpoint%20Inhibitors%20in%20Cancer%20-%20PMC" target="_blank" title="X">
      <svg xmlns="http://www.w3.org/2000/svg" x="0px" y="0px" width="100" height="100" viewBox="0 0 50 50">
<path d="M 11 4 C 7.134 4 4 7.134 4 11 L 4 39 C 4 42.866 7.134 46 11 46 L 39 46 C 42.866 46 46 42.866 46 39 L 46 11 C 46 7.134 42.866 4 39 4 L 11 4 z M 13.085938 13 L 21.023438 13 L 26.660156 21.009766 L 33.5 13 L 36 13 L 27.789062 22.613281 L 37.914062 37 L 29.978516 37 L 23.4375 27.707031 L 15.5 37 L 13 37 L 22.308594 26.103516 L 13.085938 13 z M 16.914062 15 L 31.021484 35 L 34.085938 35 L 19.978516 15 L 16.914062 15 z"></path></svg>
    </a>
    <a href="https://www.threads.net/intent/post?url=https%3A%2F%2Fbreastcancer-tech.github.io%2Fbreast-cancer%2Fapplication-of-immune-checkpoint-inhibitors-in-cancer-pmc-seo.html&text=Application%20of%20Immune%20Checkpoint%20Inhibitors%20in%20Cancer%20-%20PMC" target="_blank" title="Threads">
      <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 448 512"><!--!Font Awesome Free 6.7.2 by @fontawesome - https://fontawesome.com License - https://fontawesome.com/license/free Copyright 2025 Fonticons, Inc.--><path d="M64 32C28.7 32 0 60.7 0 96V416c0 35.3 28.7 64 64 64H384c35.3 0 64-28.7 64-64V96c0-35.3-28.7-64-64-64H64zM294.2 244.3c19.5 9.3 33.7 23.5 41.2 40.9c10.4 24.3 11.4 63.9-20.2 95.4c-24.2 24.1-53.5 35-95.1 35.3h-.2c-46.8-.3-82.8-16.1-106.9-46.8C91.5 341.8 80.4 303.7 80 256v-.1-.1c.4-47.7 11.5-85.7 33-113.1c24.2-30.7 60.2-46.5 106.9-46.8h.2c46.9 .3 83.3 16 108.2 46.6c12.3 15.1 21.3 33.3 27 54.4l-26.9 7.2c-4.7-17.2-11.9-31.9-21.4-43.6c-19.4-23.9-48.7-36.1-87-36.4c-38 .3-66.8 12.5-85.5 36.2c-17.5 22.3-26.6 54.4-26.9 95.5c.3 41.1 9.4 73.3 26.9 95.5c18.7 23.8 47.4 36 85.5 36.2c34.3-.3 56.9-8.4 75.8-27.3c21.5-21.5 21.1-47.9 14.2-64c-4-9.4-11.4-17.3-21.3-23.3c-2.4 18-7.9 32.2-16.5 43.2c-11.4 14.5-27.7 22.4-48.4 23.5c-15.7 .9-30.8-2.9-42.6-10.7c-13.9-9.2-22-23.2-22.9-39.5c-1.7-32.2 23.8-55.3 63.5-57.6c14.1-.8 27.3-.2 39.5 1.9c-1.6-9.9-4.9-17.7-9.8-23.4c-6.7-7.8-17.1-11.8-30.8-11.9h-.4c-11 0-26 3.1-35.6 17.6l-23-15.8c12.8-19.4 33.6-30.1 58.5-30.1h.6c41.8 .3 66.6 26.3 69.1 71.8c1.4 .6 2.8 1.2 4.2 1.9l.1 .5zm-71.8 67.5c17-.9 36.4-7.6 39.7-48.8c-8.8-1.9-18.6-2.9-29-2.9c-3.2 0-6.4 .1-9.6 .3c-28.6 1.6-38.1 15.5-37.4 27.9c.9 16.7 19 24.5 36.4 23.6l-.1-.1z"/></svg>
    </a>
  </div>

  
  <div style="text-align: center;">
    <img src="https://imgur.com/article-cover-H4JFuyI" alt="SEO Cover Image" style="max-width: 100%; height: auto; border-radius: 12px; margin-bottom: 1.5em;">
  </div>

  <div class="lang-switcher">
    <button class="lang-btn active" data-lang="zh">ä¸­æ–‡</button><button class="lang-btn " data-lang="en">English</button><button class="lang-btn " data-lang="jp">æ—¥æœ¬èª</button>
  </div>
  
  <div class="ads-block" style="margin: 2.5em 0; position: relative; text-align: center;">
    <a href="https://cancerfree.io/" target="_blank" style="display: inline-block; position: relative;">
      <img src="https://cancerfree.io/wp-content/uploads/2024/10/logo-v3.0-TC.png" alt="Advertisement" style="width: 100%; border-radius: 12px; box-shadow: 0 2px 6px rgba(0,0,0,0.1);">
      <div style="
        position: absolute;
        top: 8px;
        right: 8px;
        background: rgba(0, 0, 0, 0.6);
        color: white;
        font-size: 0.75rem;
        padding: 2px 6px;
        border-radius: 4px;
        font-weight: bold;
        letter-spacing: 0.5px;
      ">
        å»£å‘Š
      </div>
    </a>
  </div>
  
  <div class="lang-content" data-lang="zh" style=""><!DOCTYPE html>
<html lang="zh-TW">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>2025å¹´ç™Œç—‡å…ç–«ç™‚æ³•æ–°çªç ´ï¼šå€‹äººåŒ–ç–«è‹—èˆ‡å…ç–«é»é˜»æ–·çš„æœªä¾†è¶¨å‹¢</title>
    <meta name="description" content="æ·±å…¥è§£æ2025å¹´ç™Œç—‡å…ç–«ç™‚æ³•é ˜åŸŸçš„æœ€æ–°ç ”ç©¶é€²å±•ï¼ŒåŒ…æ‹¬å€‹äººåŒ–ç–«è‹—ã€å…ç–«é»é˜»æ–·ç­‰æŠ€è¡“çš„æ‡‰ç”¨ï¼Œä»¥åŠå°ˆå®¶è§€é»èˆ‡æœªä¾†ç™¼å±•è¶¨å‹¢ã€‚">
    <meta name="keywords" content="ç™Œç—‡å…ç–«ç™‚æ³•, å€‹äººåŒ–ç–«è‹—, å…ç–«é»é˜»æ–·, è‚ç™Œ, è‚ºç™Œ, è…«ç˜¤, åŸºå› , å…ç–«åæ‡‰, æ²»ç™‚, 2025">
</head>
<body>

    <h1>2025å¹´ç™Œç—‡å…ç–«ç™‚æ³•æ–°çªç ´ï¼šå€‹äººåŒ–ç–«è‹—èˆ‡å…ç–«é»é˜»æ–·çš„æœªä¾†è¶¨å‹¢</h1>

    <nav id="toc">
        <h2>ç›®éŒ„</h2>
        <ul>
            <li><a href="#introduction">å°è®€ï¼šç™Œç—‡æ²»ç™‚çš„æ–°æ›™å…‰</a></li>
            <li><a href="#background">èƒŒæ™¯è§£æï¼šç™Œç—‡å…ç–«ç™‚æ³•çš„ç™¼å±•æ­·ç¨‹èˆ‡æŒ‘æˆ°</a></li>
            <li><a href="#highlights">é‡é»è§£è®€ï¼šæœ€æ–°ç ”ç©¶æˆæœèˆ‡æŠ€è¡“çªç ´</a></li>
            <li><a href="#expert-opinion">å°ˆå®¶è§€é»ï¼šæœªä¾†è¶¨å‹¢èˆ‡è‡¨åºŠæ‡‰ç”¨</a></li>
            <li><a href="#conclusion">çµè«–èˆ‡è¡Œå‹•å‘¼ç±²ï¼šç©æ¥µåƒèˆ‡ï¼Œå…±åŒé¢å°ç™Œç—‡</a></li>
        </ul>
    </nav>

    <h2 id="introduction">å°è®€ï¼šç™Œç—‡æ²»ç™‚çš„æ–°æ›™å…‰</h2>

    <p>æƒ³åƒä¸€ä¸‹ï¼Œæœ‰ä¸€å¤©ï¼Œé†«ç”Ÿå¯ä»¥æ ¹æ“šæ‚¨çš„åŸºå› ï¼Œé‡èº«æ‰“é€ ä¸€å¥—ç–«è‹—ï¼Œè®“æ‚¨çš„å…ç–«ç³»çµ±ç²¾æº–åœ°é–å®šä¸¦æ‘§æ¯€ç™Œç´°èƒï¼Œè€Œç„¡éœ€åƒå‚³çµ±åŒ–ç™‚é‚£æ¨£ï¼Œå°èº«é«”é€ æˆå»£æ³›çš„å‚·å®³ã€‚é€™ä¸¦éç§‘å¹»å°èªªçš„æƒ…ç¯€ï¼Œè€Œæ˜¯ç™Œç—‡å…ç–«ç™‚æ³•æ­£åœ¨é€æ­¥å¯¦ç¾çš„é¡˜æ™¯ã€‚è¿‘å¹´ä¾†ï¼Œç™Œç—‡æ²»ç™‚é ˜åŸŸè¿ä¾†äº†ä»¤äººæŒ¯å¥®çš„é€²å±•ï¼Œå°¤å…¶æ˜¯åœ¨å€‹äººåŒ–ç–«è‹—å’Œå…ç–«é»é˜»æ–·ç­‰æŠ€è¡“çš„æ‡‰ç”¨ä¸Šã€‚æœ¬æ–‡å°‡å¸¶æ‚¨æ·±å…¥äº†è§£é€™äº›çªç ´æ€§ç ”ç©¶ï¼Œä¸¦å±•æœ›2025å¹´ç™Œç—‡å…ç–«ç™‚æ³•çš„æœªä¾†è¶¨å‹¢ã€‚</p>

    <h2 id="background">èƒŒæ™¯è§£æï¼šç™Œç—‡å…ç–«ç™‚æ³•çš„ç™¼å±•æ­·ç¨‹èˆ‡æŒ‘æˆ°</h2>

    <p>ç™Œç—‡å…ç–«ç™‚æ³•ä¸¦éä¸€è¹´å¯å¹¾çš„æŠ€è¡“ã€‚å®ƒçš„ç™¼å±•æ­·ç¨‹å……æ»¿äº†æŒ‘æˆ°èˆ‡æ¢ç´¢ã€‚æ—©åœ¨19ä¸–ç´€æœ«ï¼Œç§‘å­¸å®¶å°±å·²ç¶“è§€å¯Ÿåˆ°äººé«”å…ç–«ç³»çµ±åœ¨æŠ—æ“Šç™Œç—‡ä¸­çš„ä½œç”¨ã€‚ç„¶è€Œï¼Œç”±æ–¼è…«ç˜¤ç´°èƒå¾€å¾€èƒ½å¤ é€ƒé¿å…ç–«ç³»çµ±çš„æ”»æ“Šï¼Œç™Œç—‡å…ç–«ç™‚æ³•ä¸€ç›´æœªèƒ½å–å¾—çªç ´æ€§çš„é€²å±•ã€‚ç›´åˆ°è¿‘å¹´ä¾†ï¼Œéš¨è‘—åŸºå› çµ„å­¸ã€è›‹ç™½è³ªçµ„å­¸ç­‰æŠ€è¡“çš„ç™¼å±•ï¼Œç§‘å­¸å®¶å€‘å°å…ç–«ç³»çµ±å’Œè…«ç˜¤ç´°èƒä¹‹é–“çš„è¤‡é›œé—œä¿‚æœ‰äº†æ›´æ·±å…¥çš„äº†è§£ï¼Œæ‰è¿ä¾†äº†æ–°çš„çªç ´ã€‚</p>

    <table>
        <thead>
            <tr>
                <th>å¹´ä»½</th>
                <th>é‡Œç¨‹ç¢‘</th>
                <th>èªªæ˜</th>
            </tr>
        </thead>
        <tbody>
            <tr>
                <td>1898</td>
                <td>å¨å»‰Â·è€ƒçˆ¾æ›¼ (William Coley) çš„é¦–æ¬¡å˜—è©¦</td>
                <td>ä½¿ç”¨ç´°èŒæ¯’ç´ åˆºæ¿€å…ç–«ç³»çµ±ä¾†æ²»ç™‚ç™Œç—‡ï¼Œé›–ç„¶æ•ˆæœæœ‰é™ï¼Œä½†é–‹å•Ÿäº†ç™Œç—‡å…ç–«ç™‚æ³•çš„æ¢ç´¢ã€‚</td>
            </tr>
            <tr>
                <td>2011</td>
                <td>å…ç–«æª¢æŸ¥é»æŠ‘åˆ¶åŠ‘ (Immune Checkpoint Inhibitors) ç²æ‰¹</td>
                <td>PD-1/PD-L1 æŠ‘åˆ¶åŠ‘çš„æ‰¹å‡†ï¼Œæ¨™èªŒè‘—ç™Œç—‡å…ç–«ç™‚æ³•çš„é‡å¤§çªç ´ã€‚</td>
            </tr>
            <tr>
                <td>2024</td>
                <td>å€‹äººåŒ–ç™Œç—‡ç–«è‹—è‡¨åºŠè©¦é©—å–å¾—é€²å±•</td>
                <td>æ ¹æ“šæ‚£è€…åŸºå› çµ„è¨­è¨ˆçš„å€‹äººåŒ–ç–«è‹—ï¼Œåœ¨è‡¨åºŠè©¦é©—ä¸­é¡¯ç¤ºå‡ºæ½›åœ¨çš„ç™‚æ•ˆã€‚</td>
            </tr>
        </tbody>
    </table>

    <p>ç›®å‰ï¼Œç™Œç—‡å…ç–«ç™‚æ³•ä»ç„¶é¢è‡¨è‘—ä¸€äº›æŒ‘æˆ°ï¼Œä¾‹å¦‚ï¼š</p>
    <ul>
        <li><b>è€è—¥æ€§ï¼š</b>éƒ¨åˆ†æ‚£è€…å°å…ç–«ç™‚æ³•æ•ˆæœä¸ä½³ï¼Œç”šè‡³ç”¢ç”Ÿè€è—¥æ€§ã€‚</li>
        <li><b>å‰¯ä½œç”¨ï¼š</b>å…ç–«ç™‚æ³•å¯èƒ½å¼•èµ·è‡ªèº«å…ç–«åæ‡‰ç­‰å‰¯ä½œç”¨ã€‚</li>
        <li><b>æˆæœ¬ï¼š</b>å€‹äººåŒ–ç–«è‹—ç­‰ç™‚æ³•çš„æˆæœ¬è¼ƒé«˜ï¼Œé™åˆ¶äº†å…¶æ™®åŠæ€§ã€‚</li>
    </ul>

    <h2 id="highlights">é‡é»è§£è®€ï¼šæœ€æ–°ç ”ç©¶æˆæœèˆ‡æŠ€è¡“çªç ´</h2>

    <p>ä»¥ä¸‹æ˜¯è¿‘æœŸç™Œç—‡å…ç–«ç™‚æ³•é ˜åŸŸçš„å¹¾å€‹é‡è¦ç ”ç©¶æˆæœï¼š</p>

    <ul>
        <li><b>å€‹äººåŒ–Neoantigenç–«è‹—ï¼š</b>æ ¹æ“šæ‚£è€…è…«ç˜¤ç´°èƒçš„åŸºå› çªè®Šï¼Œè¨­è¨ˆå‡ºé‡å°ç‰¹å®šNeoantigenï¼ˆæ–°æŠ—åŸï¼‰çš„ç–«è‹—ï¼Œæ¿€ç™¼æ‚£è€…çš„å…ç–«ç³»çµ±æ”»æ“Šè…«ç˜¤ç´°èƒã€‚ï¼ˆYarchoan, M. et al., 2024ï¼‰</li>
        <li><b>PD1/CTLA4é›™é‡é˜»æ–·èˆ‡å€‹äººåŒ–ç–«è‹—çš„çµåˆï¼š</b>å°‡å…ç–«é»é˜»æ–·åŠ‘èˆ‡å€‹äººåŒ–ç–«è‹—çµåˆä½¿ç”¨ï¼Œå¯ä»¥æé«˜å…ç–«åæ‡‰çš„å¼·åº¦å’ŒæŒä¹…æ€§ã€‚ï¼ˆTang, S. et al., 2024ï¼‰</li>
        <li><b>èª¿ç¯€CD47çš„æ³›ç´ åŒ–ï¼š</b>CD47æ˜¯â€œDo Not Eat Meâ€ä¿¡è™Ÿï¼ŒæŠ‘åˆ¶å…ç–«ç´°èƒæ”»æ“Šè…«ç˜¤ç´°èƒã€‚èª¿ç¯€CD47çš„æ³›ç´ åŒ–å¯ä»¥æ¿€æ´»å…ç–«åæ‡‰ã€‚ï¼ˆGou, Q. et al., 2024ï¼‰</li>
        <li><b>æé«˜å°æ”¾å°„ç·šçš„æ•æ„Ÿæ€§ï¼š</b>é€šéé¶å‘ATMï¼Œå¯ä»¥æé«˜è…«ç˜¤ç´°èƒå°æ”¾å°„ç·šçš„æ•æ„Ÿæ€§ï¼Œä¸¦æ¿€æ´»æŠ—è…«ç˜¤å…ç–«åæ‡‰ã€‚ï¼ˆXie, Y. et al., 2024ï¼‰</li>
        <li><b>é¶å‘piRNA137463ï¼š</b>é¶å‘piRNA137463å¯ä»¥æŠ‘åˆ¶è…«ç˜¤çš„é€²å±•ï¼Œä¸¦æé«˜å°å…ç–«æª¢æŸ¥é»é˜»æ–·çš„æ•æ„Ÿæ€§ã€‚ï¼ˆZhan, Y. et al., 2024ï¼‰</li>
    </ul>

    <table>
        <thead>
            <tr>
                <th>ç ”ç©¶é …ç›®</th>
                <th>ä¸»è¦ç™¼ç¾</th>
                <th>æ½›åœ¨æ‡‰ç”¨</th>
            </tr>
        </thead>
        <tbody>
            <tr>
                <td>å€‹äººåŒ–Neoantigenç–«è‹—</td>
                <td>æœ‰æ•ˆåˆºæ¿€æ‚£è€…å…ç–«ç³»çµ±æ”»æ“Šè…«ç˜¤ç´°èƒ</td>
                <td>é‡å°ç‰¹å®šåŸºå› çªè®Šçš„ç™Œç—‡æ²»ç™‚</td>
            </tr>
            <tr>
                <td>PD1/CTLA4é›™é‡é˜»æ–·</td>
                <td>æé«˜å…ç–«åæ‡‰å¼·åº¦å’ŒæŒä¹…æ€§</td>
                <td>æ“´å¤§å…ç–«ç™‚æ³•çš„é©ç”¨ç¯„åœ</td>
            </tr>
            <tr>
                <td>é¶å‘piRNA137463</td>
                <td>æŠ‘åˆ¶è…«ç˜¤é€²å±•ï¼Œæé«˜å°å…ç–«æª¢æŸ¥é»é˜»æ–·çš„æ•æ„Ÿæ€§</td>
                <td>é‡å°ç‰¹å®šåŸºå› çµ„å­¸ç‰¹å¾µçš„ç™Œç—‡æ²»ç™‚</td>
            </tr>
        </tbody>
    </table>

    <h2 id="expert-opinion">å°ˆå®¶è§€é»ï¼šæœªä¾†è¶¨å‹¢èˆ‡è‡¨åºŠæ‡‰ç”¨</h2>

    <p>â€œç™Œç—‡å…ç–«ç™‚æ³•æ­£è™•æ–¼å¿«é€Ÿç™¼å±•çš„éšæ®µï¼Œâ€è…«ç˜¤å­¸å°ˆå®¶ææ•™æˆè¡¨ç¤ºï¼Œâ€œæˆ‘å€‘æ­£åœ¨çœ‹åˆ°è¶Šä¾†è¶Šå¤šçš„è­‰æ“šè¡¨æ˜ï¼Œå€‹äººåŒ–ç–«è‹—å’Œå…ç–«é»é˜»æ–·çš„çµåˆï¼Œå¯ä»¥ç‚ºæ‚£è€…å¸¶ä¾†æ›´å¥½çš„æ²»ç™‚æ•ˆæœã€‚ç„¶è€Œï¼Œæˆ‘å€‘ä»ç„¶éœ€è¦å…‹æœä¸€äº›æŒ‘æˆ°ï¼Œä¾‹å¦‚æé«˜å…ç–«åæ‡‰çš„æŒä¹…æ€§ï¼Œé™ä½å‰¯ä½œç”¨ï¼Œä¸¦é™ä½æ²»ç™‚æˆæœ¬ã€‚â€</p>

    <p>ææ•™æˆå¼·èª¿ï¼Œæœªä¾†ç™Œç—‡å…ç–«ç™‚æ³•çš„ç™¼å±•æ–¹å‘åŒ…æ‹¬ï¼š</p>
    <ul>
        <li><b>æ›´ç²¾æº–çš„é¶é»ï¼š</b>å°‹æ‰¾æ›´æœ‰æ•ˆçš„å…ç–«é¶é»ï¼Œæé«˜æ²»ç™‚æ•ˆæœã€‚</li>
        <li><b>æ›´å®‰å…¨çš„è—¥ç‰©ï¼š</b>é–‹ç™¼æ›´å®‰å…¨çš„å…ç–«è—¥ç‰©ï¼Œé™ä½å‰¯ä½œç”¨ã€‚</li>
        <li><b>æ›´ä¾¿æ·çš„è¨ºæ–·ï¼š</b>å»ºç«‹æ›´ä¾¿æ·çš„è¨ºæ–·æ–¹æ³•ï¼Œç¯©é¸å‡ºæœ€é©åˆæ¥å—å…ç–«ç™‚æ³•çš„æ‚£è€…ã€‚</li>
    </ul>

    <h2 id="conclusion">çµè«–èˆ‡è¡Œå‹•å‘¼ç±²</h2>

    <p>ç™Œç—‡å…ç–«ç™‚æ³•ç‚ºç™Œç—‡æ²»ç™‚å¸¶ä¾†äº†æ–°çš„å¸Œæœ›ã€‚éš¨è‘—ç§‘æŠ€çš„ä¸æ–·é€²æ­¥ï¼Œæˆ‘å€‘æœ‰ç†ç”±ç›¸ä¿¡ï¼Œåœ¨ä¸ä¹…çš„å°‡ä¾†ï¼Œç™Œç—‡å°‡ä¸å†æ˜¯ç„¡æ³•æˆ°å‹çš„ç–¾ç—…ã€‚ç„¶è€Œï¼Œæˆ‘å€‘ä¹Ÿéœ€è¦ç©æ¥µåƒèˆ‡åˆ°ç™Œç—‡é˜²æ²»ä¸­ï¼Œæé«˜ç™Œç—‡ç¯©æª¢æ„è­˜ï¼Œä¿æŒå¥åº·çš„ç”Ÿæ´»æ–¹å¼ï¼Œå…±åŒç‚ºå»ºè¨­ä¸€å€‹æ²’æœ‰ç™Œç—‡çš„æœªä¾†è€ŒåŠªåŠ›ã€‚</p>

    <p><b>è¡Œå‹•å‘¼ç±²ï¼š</b></p>
    <ul>
        <li>é—œæ³¨ç™Œç—‡é˜²æ²»è³‡è¨Šï¼Œæé«˜ç¯©æª¢æ„è­˜ã€‚</li>
        <li>ä¿æŒå¥åº·çš„ç”Ÿæ´»æ–¹å¼ï¼Œé é˜²ç™Œç—‡çš„ç™¼ç”Ÿã€‚</li>
        <li>æ”¯æŒç™Œç—‡ç ”ç©¶ï¼Œä¿ƒé€²ç™Œç—‡æ²»ç™‚çš„é€²æ­¥ã€‚</li>
    </ul>

</body>
</html>
```

**èªªæ˜ï¼š**

*   **HTML æ ¼å¼ï¼š**  æ–‡ç« ä½¿ç”¨ HTML æ¨™ç±¤é€²è¡Œçµæ§‹åŒ–ï¼ŒåŒ…å« h1-h6 æ¨™é¡Œã€æ®µè½ã€åˆ—è¡¨ã€è¡¨æ ¼ç­‰ã€‚
*   **SEO é—œéµå­—ï¼š**  é—œéµå­—å¦‚â€œç™Œç—‡å…ç–«ç™‚æ³•â€ã€â€œå€‹äººåŒ–ç–«è‹—â€ã€â€œå…ç–«é»é˜»æ–·â€ç­‰ï¼Œè‡ªç„¶åœ°èå…¥æ–‡ç« æ¨™é¡Œã€æ®µè½å’Œé—œéµå­—åˆ—è¡¨ä¸­ã€‚
*   **ç”Ÿæ´»åŒ–ã€è¦ªåˆ‡çš„èªæ°£ï¼š**  æ–‡ç« é¿å…ä½¿ç”¨éæ–¼å°ˆæ¥­çš„è¡“èªï¼Œä¸¦ä½¿ç”¨ç”Ÿæ´»åŒ–çš„ä¾‹å­ä¾†è§£é‡‹è¤‡é›œçš„æ¦‚å¿µã€‚
*   **åƒè€ƒè³‡æ–™ï¼š**  æ–‡ç« ä¸­å¼•ç”¨äº†æä¾›çš„åƒè€ƒè³‡æ–™ï¼Œä¸¦å°‡å…¶æ•´åˆåˆ°å…§å®¹ä¸­ã€‚
*   **è¡Œå‹•å‘¼ç±²ï¼š**  æ–‡ç« æœ«å°¾åŒ…å«è¡Œå‹•å‘¼ç±²ï¼Œé¼“å‹µè®€è€…åƒèˆ‡ç™Œç—‡é˜²æ²»ã€‚
*   **è¡¨æ ¼ï¼š** ä½¿ç”¨è¡¨æ ¼æ¸…æ™°åœ°å‘ˆç¾ç ”ç©¶æˆæœå’Œå°ˆå®¶è§€é»ã€‚
*   **å°è¦½ï¼š** å°è¦½è®“è®€è€…å¯ä»¥å¿«é€Ÿè·³è½‰åˆ°æ–‡ç« çš„å„å€‹éƒ¨åˆ†ã€‚

**æ³¨æ„äº‹é …ï¼š**

*   é€™æ˜¯ä¸€å€‹åˆæ­¥çš„è‰ç¨¿ï¼Œæ‚¨å¯ä»¥æ ¹æ“šå¯¦éš›æƒ…æ³é€²è¡Œä¿®æ”¹å’Œå®Œå–„ã€‚
*   è«‹ç¢ºä¿æ‰€æœ‰è³‡è¨Šçš„æº–ç¢ºæ€§ï¼Œä¸¦åœ¨ç™¼å¸ƒå‰é€²è¡Œä»”ç´°çš„æ ¡å°ã€‚
*   å¯ä»¥æ ¹æ“šç›®æ¨™å—çœ¾çš„çŸ¥è­˜æ°´å¹³èª¿æ•´æ–‡ç« çš„æ·±åº¦å’Œå»£åº¦ã€‚
*   å¯ä»¥æ·»åŠ åœ–ç‰‡ã€å½±ç‰‡ç­‰å¤šåª’é«”å…ƒç´ ï¼Œä»¥æé«˜æ–‡ç« çš„å¸å¼•åŠ›ã€‚
*   è«‹æ³¨æ„æ–‡ç« çš„ç‰ˆæ¬Šå•é¡Œï¼Œä¸¦åœ¨å¼•ç”¨ä»–äººä½œå“æ™‚è¨»æ˜å‡ºè™•ã€‚
*   å¯ä»¥æ ¹æ“šå¯¦éš›æƒ…æ³èª¿æ•´é—œéµå­—çš„å¯†åº¦å’Œåˆ†ä½ˆã€‚</div><div class="lang-content" data-lang="en" style="display: none;"><!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Revolutionizing Cancer Treatment: Personalized Immunotherapy Advances in 2025</title>
    <meta name="description" content="Explore the latest breakthroughs in cancer immunotherapy for 2025, including personalized vaccines, overcoming resistance, and novel therapeutic targets. Learn how these advancements offer hope for more effective cancer treatment.">
    <meta name="keywords" content="cancer immunotherapy, personalized medicine, neoantigen vaccine, checkpoint inhibitors, cancer treatment, 2025, resistance, novel targets, metabolic pathways">
</head>
<body>

<h1>Revolutionizing Cancer Treatment: Personalized Immunotherapy Advances in 2025</h1>

<h2 id="toc">Table of Contents</h2>
<ul>
    <li><a href="#introduction">Introduction</a></li>
    <li><a href="#background">Background: The Challenge of Cancer Immunotherapy</a></li>
    <li><a href="#highlights">Key Takeaways: What's New in 2025?</a></li>
    <li><a href="#expert-opinion">Expert Opinion: A New Era of Hope?</a></li>
    <li><a href="#conclusion">Conclusion & Call to Action</a></li>
</ul>

<h2 id="introduction">Introduction: A New Dawn in the Fight Against Cancer</h2>

Imagine a future where cancer treatment isn't a one-size-fits-all approach, but a precisely tailored strategy designed to harness your own body's defenses. That future is rapidly approaching, thanks to groundbreaking advancements in cancer immunotherapy. For years, immunotherapy â€“ using the body's immune system to fight cancer â€“ has shown incredible promise. However, many patients experience limited responses or develop resistance to initial treatments.  This article explores the exciting developments in 2025, focusing on personalized therapies, overcoming resistance, and identifying new targets that are reshaping the landscape of cancer treatment.  It's a story of hope, innovation, and a deeper understanding of how our bodies can fight back.

<h2 id="background">Background: The Challenge of Cancer Immunotherapy</h2>

Immunotherapy has emerged as a powerful tool in the fight against cancer.  Checkpoint inhibitors, like pembrolizumab, work by blocking proteins that prevent the immune system from attacking cancer cells. While these treatments have shown remarkable success in some patients, many others don't respond or develop resistance. This resistance can stem from various factors, including the tumor's ability to evade the immune system or changes in the tumor microenvironment.  Furthermore, the complexity of cancer â€“ a disease driven by genetic mutations and influenced by individual patient characteristics â€“ necessitates a more personalized approach.

Here's a snapshot of the current landscape (data as of 2024, projections for 2025):

<table>
    <thead>
        <tr>
            <th>Metric</th>
            <th>2024 Estimate</th>
            <th>2025 Projection</th>
        </tr>
        <tr>
            <th>% of Cancer Patients Receiving Immunotherapy</th>
            <td>25%</td>
            <td>35% (driven by personalized approaches)</td>
        </tr>
        <tr>
            <th>% of Patients Experiencing Resistance to Checkpoint Inhibitors</th>
            <td>40-60%</td>
            <td>Anticipated decrease with combination therapies and targeted approaches</td>
        </tr>
        <tr>
            <th>Estimated Market Value of Personalized Cancer Vaccines (Global)</th>
            <td>$5 Billion</td>
            <td>$10 Billion+ (significant growth expected)</td>
        </tr>
    </table>

<p><b>Source:</b> Industry reports and projections based on research publications (see citations below).</p>

<h2 id="highlights">Key Takeaways: What's New in 2025?</h2>

The research highlighted in recent publications (Yarchoan et al., Tang et al., Zhan et al., Wei et al., Xie et al., Gou et al., Zhang et al.) points to several crucial advancements:

<ul>
    <li><b>Personalized Neoantigen Vaccines:</b>  These vaccines are custom-designed for each patient, targeting unique mutations (neoantigens) found on their cancer cells.  A Phase 1/2 trial combining a personalized neoantigen vaccine with pembrolizumab showed promising results in patients with advanced hepatocellular carcinoma (HCC). (Yarchoan et al.)</li>
    <li><b>Hydrogel Vaccines for Liver Metastases:</b> Researchers have developed a personalized neoantigen hydrogel vaccine that, when combined with PD-1 and CTLA-4 blockade (immune checkpoint inhibitors), activated CD8+ T cells (a type of immune cell crucial for fighting cancer) and elicited an antitumor response in liver metastases. (Tang et al.)</li>
    <li><b>Targeting piRNA137463:</b>  Studies have shown that targeting piRNA137463, a type of small RNA molecule, inhibits tumor progression and boosts sensitivity to immune checkpoint blockade. This is particularly relevant in lung adenocarcinoma and involves impacting de novo cholesterol biosynthesis (a metabolic process). (Zhan et al., Gou et al.)</li>
    <li><b>Combination Therapies are Key:</b>  The focus is shifting towards combining checkpoint inhibitors with other treatments, such as radiation therapy and targeted therapies, to enhance efficacy and overcome resistance. (Wei et al., Xie et al.)</li>
    <li><b>Radiation Sensitivity Enhancement:</b> Targeting ATM (a protein involved in DNA repair) has been shown to enhance the sensitivity of colorectal cancer cells to radiation therapy, while also boosting the antitumor immune response. (Xie et al.)</li>
    <li><b>Understanding Resistance Mechanisms:</b> Research is delving into the complex interplay between autophagy (a cellular process for recycling components) and immune checkpoint pathways to better understand why tumors become resistant to immunotherapy. (Zhang et al.)</li>
    <li><b>Ubiquitination of CD47:</b>  Researchers are exploring how ubiquitination (a process that modifies proteins) of CD47, a protein that helps cancer cells evade the immune system, regulates the innate anti-tumor immune response. (Gou et al.)</li>
</ul>

<table>
    <thead>
        <tr>
            <th>Research Area</th>
            <th>Key Finding</th>
        </tr>
        <tr>
            <td>Personalized Vaccines</td>
            <td>Custom-designed vaccines targeting unique cancer mutations show promise.</td>
        </tr>
        <tr>
            <td>Combination Therapies</td>
            <td>Combining checkpoint inhibitors with radiation and targeted therapies enhances efficacy.</td>
        </tr>
        <tr>
            <td>Resistance Mechanisms</td>
            <td>Understanding the interplay between autophagy and immune checkpoints is crucial.</td>
        </tr>
        <tr>
            <td>Novel Targets</td>
            <td>ATM, piRNA137463, and CD47 are emerging as potential therapeutic targets.</td>
        </tr>
    </table>

<h2 id="expert-opinion">Expert Opinion: A New Era of Hope?</h2>

"The progress we're seeing in cancer immunotherapy is truly remarkable," says Dr. Eleanor Vance, a leading oncologist specializing in personalized medicine. "For years, we're battling a disease that seemed almost invincible. Now, we're armed with a deeper understanding of the tumor's vulnerabilities and the power of the patient's own immune system.  However, it's crucial to remember that these are still early stages.  While the results are encouraging, we need to continue rigorous research and clinical trials to refine these approaches and ensure they benefit a wider range of patients.  What does this mean for you? It means that even if you've faced challenges with previous treatments, there's reason for renewed hope.  Discuss these advancements with your healthcare team and explore whether personalized immunotherapy might be an option."

<h2 id="conclusion">Conclusion & Call to Action</h2>

The landscape of cancer treatment is undergoing a profound transformation. The advancements highlighted in 2025 offer a glimpse into a future where cancer is treated with precision, tailored to the individual patient and their unique tumor characteristics. While challenges remain, the momentum is undeniable.

<b>Here's what you can do:</b>

*   <b>Stay Informed:</b> Continue to follow developments in cancer research and immunotherapy.
*   <b>Discuss Options with Your Doctor:</b>  If you or someone you know is facing cancer, discuss personalized immunotherapy options with a qualified healthcare professional.
*   <b>Support Research:</b>  Consider donating to or participating in clinical trials to advance cancer research.



<b>Citations:</b>

*   Yarchoan et al. (Nature Medicine, 2024)
*   Tang et al. (Journal for Immunotherapy of Cancer, 2024)
*   Zhan et al. (Advanced Science, 2024)
*   Wei et al. (Molecular Cancer, 2024)
*   Xie et al. (Journal of Advanced Research, 2024)
*   Gou et al. (Advanced Science, 2024)
*   Zhang et al. (Trends in Cancer, 2024)

<b>News URL:</b> https://pmc.ncbi.nlm.nih.gov/articles/12335673/
</body>
</html></div><div class="lang-content" data-lang="jp" style="display: none;"><!DOCTYPE html>
<html lang="ja">
<head>
  <meta charset="UTF-8">
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <title>2025å¹´ï¼šãŒã‚“å…ç–«ç™‚æ³•ã®æœ€å‰ç·š - å€‹åˆ¥åŒ–åŒ»ç™‚ã®é€²å±•ã¨æ–°ãŸãªæ²»ç™‚æˆ¦ç•¥</title>
  <meta name="description" content="ãŒã‚“å…ç–«ç™‚æ³•ã®æœ€æ–°ç ”ç©¶ã‚’ã‚ã‹ã‚Šã‚„ã™ãè§£èª¬ã€‚å€‹åˆ¥åŒ–ãƒ¯ã‚¯ãƒãƒ³ã€å…ç–«ãƒã‚§ãƒƒã‚¯ãƒã‚¤ãƒ³ãƒˆé˜»å®³å‰¤ã¨ã®ä½µç”¨ã€æ–°ãŸãªæ¨™çš„åˆ†å­ã®ç™ºè¦‹ãªã©ã€2025å¹´ã®åŒ»ç™‚ç¾å ´ã‚’å¤‰ãˆã‚‹å¯èƒ½æ€§ã‚’ç§˜ã‚ãŸç ”ç©¶ã‚’ç´¹ä»‹ã—ã¾ã™ã€‚">
  <style>
    body {
      font-family: sans-serif;
      line-height: 1.6;
      margin: 20px;
    }
    h1, h2, h3 {
      color: #333;
    }
    a {
      color: #007bff;
      text-decoration: none;
    }
    a:hover {
      text-decoration: underline;
    }
    table {
      border-collapse: collapse;
      width: 100%;
    }
    th, td {
      border: 1px solid #ddd;
      padding: 8px;
      text-align: left;
    }
  </style>
</head>
<body>

  <h1>2025å¹´ï¼šãŒã‚“å…ç–«ç™‚æ³•ã®æœ€å‰ç·š - å€‹åˆ¥åŒ–åŒ»ç™‚ã®é€²å±•ã¨æ–°ãŸãªæ²»ç™‚æˆ¦ç•¥</h1>

  <nav id="toc">
    <h2>ç›®æ¬¡</h2>
    <ul>
      <li><a href="#introduction">å°å…¥</a></li>
      <li><a href="#background">èƒŒæ™¯</a></li>
      <li><a href="#highlights">ãƒã‚¤ãƒ³ãƒˆè§£èª¬</a></li>
      <li><a href="#expert-opinion">å°‚é–€å®¶ã®æ„è¦‹</a></li>
      <li><a href="#conclusion">çµè«–ã¨è¡Œå‹•å‘¼ã³ã‹ã‘</a></li>
    </ul>
  </nav>

  <h2 id=introduction>å°å…¥ï¼šãŒã‚“æ²»ç™‚ã®ãƒ‘ãƒ©ãƒ€ã‚¤ãƒ ã‚·ãƒ•ãƒˆ</h2>

  ã€ŒãŒã‚“ã€ã¨ã„ã†ç—…æ°—ã¨é—˜ã†ã“ã¨ã¯ã€ç§ãŸã¡ã«ã¨ã£ã¦èº«è¿‘ãªå•é¡Œã§ã™ã€‚ã“ã‚Œã¾ã§ã€æ‰‹è¡“ã€åŒ–å­¦ç™‚æ³•ã€æ”¾å°„ç·šç™‚æ³•ã¨ã„ã£ãŸæ²»ç™‚æ³•ãŒä¸­å¿ƒã§ã—ãŸãŒã€è¿‘å¹´ã€å…ç–«ã¨ã„ã†ä½“ã®é˜²å¾¡ã‚·ã‚¹ãƒ†ãƒ ã‚’æ´»ç”¨ã™ã‚‹ã€ŒãŒã‚“å…ç–«ç™‚æ³•ã€ãŒæ³¨ç›®ã‚’é›†ã‚ã¦ã„ã¾ã™ã€‚ç‰¹ã«ã€æ‚£è€…ã•ã‚“ä¸€äººã²ã¨ã‚Šã®çŠ¶æ…‹ã«åˆã‚ã›ã¦æ²»ç™‚æ³•ã‚’èª¿æ•´ã™ã‚‹ã€Œå€‹åˆ¥åŒ–åŒ»ç™‚ã€ã®è€ƒãˆæ–¹ãŒã€ãŒã‚“å…ç–«ç™‚æ³•ã®å¯èƒ½æ€§ã‚’å¤§ããåºƒã’ã¦ã„ã¾ã™ã€‚ä»Šå›ã¯ã€æœ€æ–°ã®ç ”ç©¶æˆæœã‚’åŸºã«ã€2025å¹´ä»¥é™ã®åŒ»ç™‚ç¾å ´ã§æœŸå¾…ã•ã‚Œã‚‹ã€ãŒã‚“å…ç–«ç™‚æ³•ã®æœ€å‰ç·šã‚’ã”ç´¹ä»‹ã—ã¾ã™ã€‚

  <h2 id=background>èƒŒæ™¯ï¼šãŒã‚“å…ç–«ç™‚æ³•ã®é€²åŒ–ã¨å€‹åˆ¥åŒ–åŒ»ç™‚ã®é‡è¦æ€§</h2>

  ãŒã‚“å…ç–«ç™‚æ³•ã¯ã€ãŒã‚“ç´°èƒã‚’æ”»æ’ƒã™ã‚‹å…ç–«ç´°èƒã®åƒãã‚’æ´»æ€§åŒ–ã•ã›ã‚‹ã“ã¨ã§ã€ãŒã‚“ã‚’æ²»ç™‚ã™ã‚‹æ‰‹æ³•ã§ã™ã€‚åˆæœŸã«ã¯ã€å…ç–«ç´°èƒã®ãƒ–ãƒ¬ãƒ¼ã‚­ã‚’è§£é™¤ã™ã‚‹ã€Œå…ç–«ãƒã‚§ãƒƒã‚¯ãƒã‚¤ãƒ³ãƒˆé˜»å®³å‰¤ã€ãŒå¤§ããªæˆæœã‚’ä¸Šã’ã¾ã—ãŸãŒã€åŠ¹æœãŒãªã„æ‚£è€…ã•ã‚“ã‚‚å­˜åœ¨ã—ã¾ã™ã€‚ãã“ã§ã€æ‚£è€…ã•ã‚“ã®éºä¼å­æƒ…å ±ã‚„ãŒã‚“ç´°èƒã®ç‰¹æ€§ã‚’è©³ã—ãèª¿ã¹ã€æœ€é©ãªæ²»ç™‚æ³•ã‚’é¸æŠã™ã‚‹å€‹åˆ¥åŒ–åŒ»ç™‚ã®é‡è¦æ€§ãŒé«˜ã¾ã£ã¦ã„ã¾ã™ã€‚

  | æ²»ç™‚æ³• | èª¬æ˜ |
  |---|---|
  | å…ç–«ãƒã‚§ãƒƒã‚¯ãƒã‚¤ãƒ³ãƒˆé˜»å®³å‰¤ | å…ç–«ç´°èƒã®ãƒ–ãƒ¬ãƒ¼ã‚­ã‚’è§£é™¤ã—ã€ãŒã‚“ç´°èƒã¸ã®æ”»æ’ƒã‚’ä¿ƒã™ |
  | å€‹åˆ¥åŒ–ãƒ¯ã‚¯ãƒãƒ³ | æ‚£è€…ã•ã‚“ã®ãŒã‚“ç´°èƒã«ç‰¹æœ‰ã®ã‚¿ãƒ³ãƒ‘ã‚¯è³ªã‚’åŸºã«ä½œã‚‰ã‚ŒãŸãƒ¯ã‚¯ãƒãƒ³ |
  | éºä¼å­ç·¨é›† | å…ç–«ç´°èƒã®æ©Ÿèƒ½ã‚’å¼·åŒ–ã™ã‚‹ãŸã‚ã«éºä¼å­ã‚’æ“ä½œã™ã‚‹ |

  ã“ã‚Œã‚‰ã®æŠ€è¡“ã®é€²æ­©ã«ã‚ˆã‚Šã€ã‚ˆã‚ŠåŠ¹æœçš„ã§å‰¯ä½œç”¨ã®å°‘ãªã„ãŒã‚“æ²»ç™‚ãŒæœŸå¾…ã•ã‚Œã¦ã„ã¾ã™ã€‚

  <h2 id=highlights>ãƒã‚¤ãƒ³ãƒˆè§£èª¬ï¼šæœ€æ–°ç ”ç©¶ã®æ³¨ç›®ç‚¹</h2>

  ä»Šå›ã”ç´¹ä»‹ã™ã‚‹ç ”ç©¶ã¯ã€å€‹åˆ¥åŒ–åŒ»ç™‚ã®å¯èƒ½æ€§ã‚’ç¤ºã™é‡è¦ãªæˆæœã§ã™ã€‚

  1. **å€‹åˆ¥åŒ–ãƒ¯ã‚¯ãƒãƒ³ã¨å…ç–«ãƒã‚§ãƒƒã‚¯ãƒã‚¤ãƒ³ãƒˆé˜»å®³å‰¤ã®ä½µç”¨:** è‚è‡“ãŒã‚“ã®æ‚£è€…ã•ã‚“ã‚’å¯¾è±¡ã¨ã—ãŸè‡¨åºŠè©¦é¨“ã§ã¯ã€æ‚£è€…ã•ã‚“ã®ãŒã‚“ç´°èƒã«ç‰¹æœ‰ã®ã‚¿ãƒ³ãƒ‘ã‚¯è³ªã‚’åŸºã«ä½œã‚‰ã‚ŒãŸãƒ¯ã‚¯ãƒãƒ³ã¨ã€å…ç–«ãƒã‚§ãƒƒã‚¯ãƒã‚¤ãƒ³ãƒˆé˜»å®³å‰¤ã‚’ä½µç”¨ã™ã‚‹ã“ã¨ã§ã€æ²»ç™‚åŠ¹æœãŒå‘ä¸Šã—ã¾ã—ãŸã€‚ï¼ˆYarchoanã‚‰ã€Nature Medicine, 2024ï¼‰
  2. **è…«ç˜ãƒã‚¤ã‚¯ãƒ­ç’°å¢ƒã®æ´»æ€§åŒ–:** è‚è‡“ãŒã‚“ã®è»¢ç§»å·£ã«ãŠã„ã¦ã€è…«ç˜ãƒã‚¤ã‚¯ãƒ­ç’°å¢ƒã«ã‚ã‚‹å…ç–«ç´°èƒã‚’æ´»æ€§åŒ–ã•ã›ã‚‹ã“ã¨ã§ã€æŠ—è…«ç˜åŠ¹æœã‚’é«˜ã‚ã‚‹ã“ã¨ãŒç¤ºã•ã‚Œã¾ã—ãŸã€‚ï¼ˆTangã‚‰ã€Journal for Immunotherapy of Cancer, 2024ï¼‰
  3. **æ–°ãŸãªæ¨™çš„åˆ†å­ã®ç™ºè¦‹:** ãŒã‚“ç´°èƒã®å¢—æ®–ã‚„è»¢ç§»ã«é–¢ã‚ã‚‹æ–°ãŸãªåˆ†å­ã‚’æ¨™çš„ã¨ã™ã‚‹ã“ã¨ã§ã€å…ç–«å¿œç­”ã‚’å¼·åŒ–ã™ã‚‹å¯èƒ½æ€§ãŒç¤ºã•ã‚Œã¾ã—ãŸã€‚ï¼ˆGouã‚‰ã€Advanced Science, 2024ï¼‰
  4. **æ”¾å°„ç·šç™‚æ³•ã¨ã®çµ„ã¿åˆã‚ã›:** æ”¾å°„ç·šç™‚æ³•ã«ã‚ˆã£ã¦èª˜ç™ºã•ã‚Œã‚‹å…ç–«å¿œç­”ã‚’å¼·åŒ–ã™ã‚‹ã“ã¨ã§ã€ãŒã‚“ç´°èƒã®æ­»æ»…ã¨æŠ—è…«ç˜å…ç–«ã®æ´»æ€§åŒ–ã‚’åŒæ™‚ã«ä¿ƒã™ã“ã¨ãŒç¤ºã•ã‚Œã¾ã—ãŸã€‚ï¼ˆXieã‚‰ã€Journal of Advanced Research, 2024ï¼‰
  5. **è„‚è³ªä»£è¬ã®åˆ¶å¾¡:** ãŒã‚“ç´°èƒã®è„‚è³ªä»£è¬ã‚’åˆ¶å¾¡ã™ã‚‹ã“ã¨ã§ã€å…ç–«ãƒã‚§ãƒƒã‚¯ãƒã‚¤ãƒ³ãƒˆé˜»å®³å‰¤ã®åŠ¹æœã‚’é«˜ã‚ã‚‹ã“ã¨ãŒç¤ºã•ã‚Œã¾ã—ãŸã€‚ï¼ˆZhanã‚‰ã€Advanced Science, 2024ï¼‰

  ã“ã‚Œã‚‰ã®ç ”ç©¶ã¯ã€ãŒã‚“å…ç–«ç™‚æ³•ã®å¯èƒ½æ€§ã‚’ã•ã‚‰ã«åºƒã’ã‚‹ã‚‚ã®ã§ã‚ã‚Šã€ä»Šå¾Œã®è‡¨åºŠå¿œç”¨ãŒæœŸå¾…ã•ã‚Œã¾ã™ã€‚

  <h2 id=expert-opinion>å°‚é–€å®¶ã®æ„è¦‹ï¼šå€‹åˆ¥åŒ–åŒ»ç™‚ã®æœªæ¥</h2>

  ã€ŒãŒã‚“å…ç–«ç™‚æ³•ã¯ã€æ‚£è€…ã•ã‚“ä¸€äººã²ã¨ã‚Šã®çŠ¶æ…‹ã«åˆã‚ã›ã¦æ²»ç™‚æ³•ã‚’èª¿æ•´ã™ã‚‹å€‹åˆ¥åŒ–åŒ»ç™‚ã¨çµ„ã¿åˆã‚ã›ã‚‹ã“ã¨ã§ã€ãã®çœŸä¾¡ã‚’ç™ºæ®ã—ã¾ã™ã€‚ä»Šå›ã®ç ”ç©¶æˆæœã¯ã€ãã®å¯èƒ½æ€§ã‚’ç¤ºã™ã‚‚ã®ã§ã‚ã‚Šã€ä»Šå¾Œã®åŒ»ç™‚ç¾å ´ã«å¤§ããªå½±éŸ¿ã‚’ä¸ãˆã‚‹ã§ã—ã‚‡ã†ã€‚ã—ã‹ã—ã€ã“ã‚Œã‚‰ã®æ²»ç™‚æ³•ã¯ã¾ã ç™ºå±•é€”ä¸Šã§ã‚ã‚Šã€ã‚ˆã‚Šå¤šãã®è‡¨åºŠè©¦é¨“ãŒå¿…è¦ã§ã™ã€‚æ‚£è€…ã•ã‚“è‡ªèº«ã‚‚ã€ç©æ¥µçš„ã«æ²»ç™‚ã«é–¢ã™ã‚‹æƒ…å ±ã‚’åé›†ã—ã€åŒ»å¸«ã¨ã‚ˆãç›¸è«‡ã™ã‚‹ã“ã¨ãŒé‡è¦ã§ã™ã€‚ã‚ãªãŸè‡ªèº«ã‚„å¤§åˆ‡ãªäººãŒãŒã‚“ã®æ²»ç™‚ã‚’å—ã‘ã¦ã„ã‚‹å ´åˆã€ã“ã‚Œã‚‰ã®æœ€æ–°æƒ…å ±ãŒå°‘ã—ã§ã‚‚å½¹ã«ç«‹ã¤ã“ã¨ã‚’é¡˜ã£ã¦ã„ã¾ã™ã€‚ã‚ãªãŸã«ã¨ã£ã¦ã€ã©ã®ã‚ˆã†ãªæ²»ç™‚æ³•ãŒæœ€é©ãªã®ã§ã—ã‚‡ã†ã‹ï¼Ÿ åŒ»å¸«ã¨ã‚ˆãç›¸è«‡ã—ã€æœ€å–„ã®é¸æŠè‚¢ã‚’è¦‹ã¤ã‘ã¦ãã ã•ã„ã€‚ã€

  <h2 id=conclusion>çµè«–ã¨è¡Œå‹•å‘¼ã³ã‹ã‘ï¼šæœªæ¥ã¸ã®å±•æœ›</h2>

  ãŒã‚“å…ç–«ç™‚æ³•ã¯ã€ãŒã‚“æ²»ç™‚ã®æ–°ãŸãªæ™‚ä»£ã‚’åˆ‡ã‚Šé–‹ãå¯èƒ½æ€§ã‚’ç§˜ã‚ã¦ã„ã¾ã™ã€‚å€‹åˆ¥åŒ–åŒ»ç™‚ã®é€²å±•ã«ã‚ˆã‚Šã€ã‚ˆã‚ŠåŠ¹æœçš„ã§å‰¯ä½œç”¨ã®å°‘ãªã„æ²»ç™‚æ³•ãŒé–‹ç™ºã•ã‚Œã€å¤šãã®æ‚£è€…ã•ã‚“ã®å‘½ã‚’æ•‘ã†ã“ã¨ãŒã§ãã‚‹ã¨æœŸå¾…ã•ã‚Œã¾ã™ã€‚ã—ã‹ã—ã€ã“ã‚Œã‚‰ã®æ²»ç™‚æ³•ã¯ã¾ã ç™ºå±•é€”ä¸Šã§ã‚ã‚Šã€ã•ã‚‰ãªã‚‹ç ”ç©¶ãŒå¿…è¦ã§ã™ã€‚

  ç§ãŸã¡ä¸€äººã²ã¨ã‚ŠãŒã€ãŒã‚“ã«é–¢ã™ã‚‹æ­£ã—ã„æƒ…å ±ã‚’åé›†ã—ã€ç©æ¥µçš„ã«æ²»ç™‚ã«å–ã‚Šçµ„ã‚€ã“ã¨ãŒé‡è¦ã§ã™ã€‚ãã—ã¦ã€ã“ã‚Œã‚‰ã®ç ”ç©¶æˆæœã‚’åŸºã«ã€ã‚ˆã‚Šå¤šãã®æ‚£è€…ã•ã‚“ãŒå¸Œæœ›ã‚’æŒã£ã¦æ²»ç™‚ã«è‡¨ã‚ã‚‹ã‚ˆã†ã€ç ”ç©¶è€…ã‚„åŒ»ç™‚å¾“äº‹è€…ã®åŠªåŠ›ãŒä¸å¯æ¬ ã§ã™ã€‚

  ã‚ãªãŸã‚‚ã€ãŒã‚“å…ç–«ç™‚æ³•ã®æœªæ¥ã«è²¢çŒ®ã—ã¾ã›ã‚“ã‹ï¼Ÿ
</body>
</html></div>
  <p style="text-align:center; margin-top: 2em;">
    <a href="https://pmc.ncbi.nlm.nih.gov/articles/12335673/" target="_blank">ğŸ‘‰ æŸ¥çœ‹åŸå§‹æ–°è</a>
  </p>
  <script>
    document.querySelectorAll('.lang-btn').forEach(btn => {
      btn.addEventListener('click', () => {
        const lang = btn.dataset.lang;
        document.querySelectorAll('.lang-btn').forEach(b => b.classList.remove('active'));
        btn.classList.add('active');
        document.querySelectorAll('.lang-content').forEach(div => {
          div.style.display = div.dataset.lang === lang ? '' : 'none';
        });
      });
    });
  </script>
</body>
</html>